Signaling of IL-4 and IL-13–two of the key drivers of type 2 inflammation–
plays an important role in PN3,4

Increased IL-4 and IL-13 signaling directly enhances stimulation of sensory neurons and also leads
to dysregulation of the immune system and skin, resulting in the itch-scratch cycle and the
formation of nodules4-11

THE DISTINCT AND
OVERLAPPING ROLES OF
IL‑4 AND IL‑134‑11

The unique role of IL-4 IN TYPE 2 INFLAMMATION

IL-4 is an orchestrator of Th2
response, creating a positive
feedback
loop that leads to dysregulated
secretion of IL-4,
IL-13, and IL-3112,b

bType 2 cytokines (such as IL-4, IL-13, and IL-31)
may also be produced by other immune cells, such
as ILC2.13,14

Diagram of type 2 cytokines creating a closed positive feedback loop

bType 2 cytokines (eg, IL-4/IL-13/IL-31) may also be produced by other immune cells, such as
ILC2.13,14

DUPIXENT is the only dual inhibitor of IL-4 and IL-13 signaling1,2

INHIBITION OF IL-4 AND IL-13
SIGNALING HAS A SUBSTANTIAL
IMPACT ON DISEASE

HELPS REDUCE TYPE 2
INFLAMMATION1,3-6,11

HELPS REDUCE
ITCH1,7,15-17

HELPS ACHIEVE
NODULE CLEARANCE1,8-10

  • May break itch-scratch cycle
  • May reduce nerve sensitization
+
  • Helps reduce skin fibrosis

The mechanism of dupilumab action has not been definitively established.

c Dimerization is when 2 protein subunits combine to form a larger complex. Complex IL-4 signaling through type 1 receptor requires dimerization of
IL-4Rα with the gamma chain. IL-4 or IL-13 signaling through type 2 receptor requires dimerization of IL-4Rα with IL-13Rα1.

Identifying DUPIXENT patients

Consider whether your patient with prurigo nodularis may be a
candidate for DUPIXENT. Take a look at real DUPIXENT stories.

VIEW REAL PATIENTS